Indian Pricing Watchdog NPPA Turns Down Requests For Insulin Price Hike; Lilly Moves To Court
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Several global pharmaceutical firms are heading for a collision with India's National Pharmaceutical Pricing Authority after the drug price regulator turned down their requests for an upward price revision of leading imported brands
You may also be interested in...
India Watchdog Seeks Expanded Powers to Review Imported Drug Prices
If NPPA investigates issues like landed costs of imported brands, it could bring about a more level playing field, industry sources say.
Indian Parliamentary Committee Lashes Out At Pricing Watchdog NPPA
NEW DELHI - Concerned by the slugglish performance of the pricing of medicines - in recovering funds from defaulting drug makers, the Parliamentary Standing Committee on chemicals and fertilizers has asked the National Pharmaceuticals Pricing Authority to bring the process up to speed
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).